AngioDynamics Announces: Dr. Thomas Sos Presenting At the TCT 2002 Conference.Business Editors/Health & Medical Writers TCT TCT The Capital Times (Madison, WI newspaper) TCT Transcatheter Cardiovascular Therapeutics TCT The Coroner's Toolkit TCT Trans Canada Trail TCT Tcl Core Team TCT Tsukuba College of Technology (Japan) 2002 Conference QUEENSBURY, N.Y.--(BUSINESS WIRE)--Sept. 24, 2002 AngioDynamics, Inc., a wholly-owned subsidiary of E-Z-EM, Inc., (AMEX AMEX See: American Stock Exchange : EZM.A and EZM.B) announced today that Dr. Thomas Sos, Professor and Vice Chairman of Radiology and Past Chief of Interventional Radiology of New York Presbyterian Hospital, will be presenting on the Feasibility of MRA MRA Medical Record Administrator. MRA Magnetic resonance angiography, see MR angiography with a MR transparent stent, the AngioDynamics Biliary OmniFlex(TM) 15mm Platinum Stent at the Transcatheter Cardiovascular Therapeutics (TCT) 2002 conference in Washington, DC. In addition, Dr. Sos will also be presenting on September 27th on the "Top 10 Tips for Renal Stenting". The OMNIFLEX(TM) 15MM BILIARY STENT is Magnetic Resonance Angiography Magnetic resonance angiography A noninvasive diagnostic technique that uses radio waves to map the internal anatomy of the blood vessels. Mentioned in: Cerebral Aneurysm magnetic resonance angiography (MRA) compatible due to its platinum material and design characteristics. The platinum OMNIFLEX(TM) is nonferromagnetic, which has been shown to produce significantly less artifacts artifacts see specimen artifacts. than stainless steel or nitinol stents during MRA procedures. Artifacts can reduce the visibility of the lumen and make accurate assessment of the patency pa·ten·cy n. The state or quality of being open, expanded, or unblocked. patency the condition of being open. of that lumen more difficult. Commenting on the announcement, Eamonn P. Hobbs, President/CEO of AngioDynamics, said, "AngioDynamics is pleased to have such a well respected expert in his field present on his clinical experience with the AngioDynamics Stent at this international conference." The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic Fluoroscopic (fluoroscopy) An x-ray procedure that produces immediate images and motion on a screen. The images look like those seen at airport baggage security stations. Mentioned in: Hypotonic Duodenography procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended March 2, 2002, as well as its Annual Report on Form 10-K for the year ended June 2, 2001, may affect the actual results achieved by the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion